Community Health Media
  • Home
  • What We Do
  • Playlists
  • Content Library
    • HER2+
    • HR+
    • HER2-Low / Ultra-Low
    • Triple Negative
    • High Risk
  • Podcasts
    • Breast Friends
    • Apple Podcasts
    • Spotify
    • Amazon Music
    • iHeartRadio
    • Castbox
    • Goodpods
    • Pocket Casts
  • Contact Us
  • ···
        • Youtube
        • Facebook
        • LinkedIn
        • Instagram
    Community Health Media
    • Home
    • What We Do
    • Playlists
    • Content Library
      • HER2+
      • HR+
      • HER2-Low / Ultra-Low
      • Triple Negative
      • High Risk
    • Podcasts
      • Breast Friends
      • Apple Podcasts
      • Spotify
      • Amazon Music
      • iHeartRadio
      • Castbox
      • Goodpods
      • Pocket Casts
    • Contact Us
    • ···
          • Youtube
          • Facebook
          • LinkedIn
          • Instagram
      Community Health Media
      • Home
      • What We Do
      • Playlists
      • Content Library
        • HER2+
        • HR+
        • HER2-Low / Ultra-Low
        • Triple Negative
        • High Risk
      • Podcasts
        • Breast Friends
        • Apple Podcasts
        • Spotify
        • Amazon Music
        • iHeartRadio
        • Castbox
        • Goodpods
        • Pocket Casts
      • Contact Us

      Why HER2+ Disease Has a Predisposition for Brain Metastases

      Dr. Kang breaks down why HER2+ breast cancer has a tendency to spread to the brain — from tumor biology to treatment limitations. Understanding CNS risk is key to proactive imaging and early intervention.

      FacebookXRedditPinterestEmail

      You may also like

      Video

      Dr. Jason Mouabbi, Dr. Irene Kang, and Dr. Ruemu Birhiray – Beyond pCR and Toward Brain Protection

      1 min read
      Video

      pCR Isn’t the Whole Story: How Oncologists Communicate Risk

      1 min read
      Video

      Should We Screen for Brain Metastases in HER2+ Disease?

      1 min read
      Video

      Does pCR Protect Against Brain Recurrence?

      1 min read
      Video

      The 12-Month Rule: Why Completing Neratinib Matters

      1 min read
      Video

      Neratinib: Unique Reduction of CNS Recurrence Risk in the Extended Adjuvant Setting

      1 min read

      Recommended Videos

      Cleopatra, DESTINY-Breast09 & What Comes Next – Drs. Bill Gradishar, Tarah Ballinger, & Megan Kruse

      4 months ago

      DESTINY-Breast09 & the Future of Care – Dr. Irene Kang & Dr. Aditya Bardia

      4 months ago

      Datopotamab Deruxtecan vs Sacituzumab Govitecan Explained – Dr. Bill Gradishar & Dr. Tiffany Traina

      4 months ago

      New First-Line Strategies in HER2+ Metastatic Breast Cancer – Dr. Mark Pegram & Dr. Carol Tweed

      4 months ago

      Community Health Ventures

      Address:

      2471 18th St NW
      Second Floor
      Washington, DC 20009

      Email: info@communityhealth.media

      Follow Us

      • youtube
      • facebook
      • linkedin
      • instagram

      Quick Links

      • About
      • KOL Playlists
      • Contact Us
      • Privacy Policy
      • Terms of Use

      Content By Topics

      • HER2+
      • HR+
      • Triple Negative
      • HER2-Low / Ultra-Low
      • High Risk

      Podcast Network

      • Breast Friends Podcast
      • Apple Podcasts
      • Spotify
      • Amazon Music
      • Castbox
      • Goodpods
      • iHeartRadio
      • Pocket Casts
      © 2026 Community Health Technologies, Inc. All Rights Reserved